Found 5 biostatistics-and-epidemiology trials
A listing of biostatistics-and-epidemiology medical research trials actively recruiting patient volunteers. Search for closest city to find more detailed information on a research study in your area.
Understanding the Genetics of Central Centrifugal Cicatricial Alopecia
The purpose of this study is to characterize gene mutations associated Central Centrifugal Cicatricial Alopecia (CCCA). The Penn Medicine BioBank (PMBB) supports researchers by providing centralized access to a large number of annotated blood and tissue samples. Clinician identified patients with CCCA and appropriate controls will be recruited from the …
Study to Investigate CSL112 in Subjects With Acute Coronary Syndrome (AEGIS-II)
Phase 3
This is a multicenter, double-blind, randomized, placebo-controlled, parallel-group study to evaluate the efficacy and safety of CSL112 on reducing the risk of major adverse CV events (MACE) in subjects with Acute Coronary Syndrome (diagnosed with STEMI or NSTEMI), who are receiving evidence-based medical therapy.
Addressing Barriers to Engagement with Harm Reduction Services for Opioid Overdose Prevention
Help us understand how to better prevent harm in people who use drugs. If you are over 18, live or work in New York City, and have used drugs in the past 3 months, then you may qualify for a research study on your experiences with harm reduction health services. Eligible …
Combination Ipatasertib and Atezolizumab to Prevent Recurrence in Triple Negative Breast Cancer
Phase 2
The purpose of this study is to determine if a combination of two drugs, Ipatasertib and Atezolizumab, works as a treatment for residual cancer in breast or lymph nodes and have circulating tumor DNA in blood. Eligible subjects will be those with triple negative breast cancer.
Utility of Parametric Response Mapping In Allograft Monitoring After Lung Transplant
The purpose is to investigate whether parametric response mapping measurements in healthy lung allografts can be used for early detection, prognostication, and phenotyping of CLAD. The target population is bilateral lung transplant recipients who are 6 months post-transplant or later and CLAD free at any of the study institutions. At …
